Breast Cancer

Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting.

Nancy Lin, MD, of the Susan F. Smith Center for Women's Cancers at the Dana Farber Cancer Institute, discusses the differences between breast cancer subtypes and looks at recent drug approvals and research directions for the future.

This presentation by Carol DeSantis, MPH, an epidemiologist with the American Cancer Society (ACS), covers key findings and statistics from the ACS report "Breast Cancer Facts and Figures 2013-2014."

The United States stands to be a key player in the global oncology biosimilars market, which is predicted to generate up to $12 billion in revenue by 2020.

According to a retrospective study and a registry analysis, statin therapy may reduce the rate of local breast cancer recurrence in certain types of breast cancer.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses emerging trends in the treatment of cancer that specialty pharmacies need to be aware of.

LBH589, when used in combination with bortezomib and dexamethasone, improved progression-free survival among relapsed and refractory patients with multiple myeloma.

A genetic test in development by Micromedic may help identify patients who are likely to develop bisphosphonate-associated osteonecrosis of the jaw.

Global oncology trend report finds that increased use of hospital outpatient facilities shifts cost burden to patients.

Findings presented at 50th Annual Meeting of ASCO show aromatase inhibitor effective for premenopausal women when combined with ovarian function suppression.

Results from 2 large, long-term clinical trials show benefits of extended-duration treatment with tamoxifen, resulting in an update to treatment guidelines.

Using a very high sensitivity assay analyzing changes in levels of MPO and troponin I before, and 3 months after starting a chemotherapy regimen, investigators were able to predict 46.5% of cases of chemotherapy-associated cardiotoxicity before they occurred.

Case studies involving hot flashes and malaria prophylaxis.

Women diagnosed with ductal carcinoma in situ, a noninvasive breast malignancy, may be more likely to choose surgery over noninvasive options when the condition is described using the word "cancer."

New research suggests that yoga may help cancer survivors sleep more and sleep better after treatment.

Those concerned about different types of cancer should band together to support research into prevention, detection, and cure-and to counter the exorbitant expense of treatment.

A study including 10 million patients covered by 11 health plans suggested that insurance claims could be used to estimate the number of early-stage breast cancer cases as well as the demand for anti-HER2 drugs.

Keeping up with advances in oncology is a welcome challenge.

Incremental gains in survival and new targeted agents in the pipeline offer promise.

Women who regularly took low-dose aspirin had significantly reduced risk of colon cancer, but researchers are not yet ready to generally recommend the drug for primary prevention.

Independent verification of drug doses can prevent mix-ups and misinterpretation.

The FDA approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.